Byondis BV, a Netherlands-based, independent, privately held, clinical stage biopharmaceutical company, announced on Thursday that it has named Professor Timo K van den Berg, PhD as its new senior director, Immuno-Oncology Research and Development effective 1 September 2021.
Prof Van den Berg will operate out of the company's headquarters in Nijmegen. In the new role, ProfVan den Berg will help shape the company's IO pipeline, which includes the anti-SIRP alpha monoclonal antibody BYON4228.
Prof Van den Berg has over 30 years of experience in the IO field. He has served as head and principal investigator, Immunotherapy Laboratory, Department of Molecular Haematology at Sanquin Research, Amsterdam, the Netherlands and professor of Immunotherapy, Vrije Universiteit. He has 25 years of experience as research group leader and department head at Amsterdam University Medical Center and Sanquin Research. He is a member of many boards, including Amsterdam Infection and Immunity Institute and Cancer Center Amsterdam and his professional memberships include the Dutch Society of Immunology and the European Society for Clinical Investigation.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer